Amy Madden
Family · Trumann, ARNPI 1710110051
Payments from drug & device makers
Across 46 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$194
- Novo Nordisk$125
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$104
- Lilly USA, LLC$72
- GSK$51
- Genentech USA, Inc.$46
- plus $167 from 10 others
What the payments were for
- Food & beverage$759100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 7 | $194 |
| Novo Nordisk | 8 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $104 |
| Lilly USA, LLC | 5 | $72 |
| GSK | 3 | $51 |
| Genentech USA, Inc. | 4 | $46 |
| Bayer | 2 | $26 |
| Boehringer Ingelheim | 2 | $25 |
| Pfizer | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| AbbVie | 1 | $17 |
| Almatica Pharma LLC | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Amgen | 1 | $13 |
| Boston Scientific | 1 | $13 |
| Phathom Pharmaceuticals, Inc. | 1 | $10 |
How this compares
$759 in reported general payments places this provider in the 60th percentile of 2,103 family providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefdinir | 72 | $1,330 |
| Ondansetron OdtOndansetron | 50 | $606 |
| Doxycycline Hyclate | 43 | $519 |
| Methylprednisolone | 76 | $485 |
| Azithromycin | 94 | $422 |
| Cephalexin | 50 | $313 |
| Dexamethasone | 57 | $309 |
| Prednisone | 160 | $269 |
| Ciprofloxacin Hcl | 21 | $172 |
| Amoxicillin | 34 | $139 |
| Levofloxacin | 23 | $106 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $79 |
| Fluconazole | 16 | $75 |
| Cyclobenzaprine Hcl | 21 | $75 |
| Metronidazole | 11 | $57 |
Paid to pharmacies, not to this prescriber.
Other family in Trumann
- Leah CarringtonRogers$1.6M
- Nina CopelandFort Smith$207K
- Stefanie BrackinJonesboro$51K
- Amanda DavisFort Smith$46K
- Allison HittManila$40K
- Kimberly GatesNorth Little Rock$31K
- Meghan MallettConway$25K
- Anthony EcholsLittle Rock$25K
- Shelby CochranFayetteville$23K
- Michael StirlingLittle Rock$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.